To investigate whether Sp1 and Smad3 elicit a synergetic effect on TGF‐β‐induced upregulation of EGFR expression, on the basis of Smad3 knockdown, we used the Sp1 inhibitor MTM to treat breast cancer cells. Here, SP1 is linked to breast carcinoma.